Share NeoGenomics Touts 29% Sequencing Growth, Plans Sales Push for Cancer Tests

MarketBeat · NEO · November 21, 2026

NeoGenomics Touts 29% Sequencing Growth, Plans Sales Push for Cancer Tests

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: MarketBeat ↗